Press Releases

 
Press Releases
  Date Title and Summary View
Feb 6, 2017
CRANBURY, N.J., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will participate in a corporate overview and fireside chat at the Leerink Partners 6th Annual Global Healthcare Co...
PDF
Jan 24, 2017
CRANBURY, N.J., Jan. 24, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that 3 oral presentations and 9 posters highlighting its development programs for Lysosomal Storage Disorders will be included at the 13th Annual WORLDSympo...
PDF
Jan 9, 2017
Strong Momentum for Galafold Launch in Europe and Multiple Global Regulatory Submissions Ahead Additional Data from Pompe Phase 1/2 Clinical Study and Top-Line Data from Phase 3 Epidermolysis Bullosa Study Expected in 2017 $331M Cash Balance with Runway Into 2H18 CRANBURY, N.J., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (...
PDF
Jan 4, 2017
Reimbursement Secured for Patients in England Commercial Launch in England, Wales and Northern Ireland Anticipated in Early 2017 CRANBURY, N.J., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced that the National Institute for Hea...
PDF
Dec 23, 2016
CRANBURY, N.J., Dec. 23, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 35th Annual J.P. Morgan Healthcare Conference in San Fr...
PDF
Dec 21, 2016
CRANBURY, N.J., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, announced the closing of its previously announced private offering of $250 million aggregate principal amount of 3.00% convertible senior notes due 2023 (the "notes"), including the full...
PDF
Dec 15, 2016
CRANBURY, N.J., Dec. 15, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced that it has priced its previously announced private offering of $225 million aggregate principal amount of 3.00% convertible senior notes due 2023 (the "notes") in a priv...
PDF
Dec 14, 2016
CRANBURY, N.J., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, announced today that it intends to offer $225,000,000 aggregate principal amount of convertible senior notes due 2023 (the "notes") in a private placement under the Securities Act of 193...
PDF
Dec 8, 2016
ATB200/AT2221 Safety Data Show No Infusion-Associated Reactions Following 100+ Infusions Clinical Pharmacokinetic (PK) Profile as Predicted Based on Previously Reported Preclinical Data Biomarkers of Muscle Damage are Generally Stable or Trending Towards Improvement Conference Call at 8:30am ET CRANBURY, N.J., Dec. ...
PDF
Nov 28, 2016
Regulatory Plan for Full Approval Pathway Based on Generation of Additional Gastrointestinal Symptoms Data Intermediate Expanded Access Program Expected to Begin in 2017 Conference Call Today at 4:30pm ET CRANBURY, N.J., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of ...
PDF
Page: FirstPrevious
2
... NextLast